Andrew David Wilcock, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medicare Part C | 3 | 2024 | 335 | 1.090 |
Why?
|
| Telemedicine | 10 | 2023 | 3105 | 0.920 |
Why?
|
| Medicare | 14 | 2024 | 6823 | 0.830 |
Why?
|
| Cachexia | 2 | 2013 | 200 | 0.730 |
Why?
|
| Hospitals | 6 | 2022 | 3888 | 0.720 |
Why?
|
| Reperfusion | 1 | 2021 | 267 | 0.670 |
Why?
|
| Economics, Hospital | 1 | 2021 | 208 | 0.650 |
Why?
|
| Ischemic Attack, Transient | 3 | 2022 | 870 | 0.640 |
Why?
|
| Reimbursement Mechanisms | 2 | 2021 | 672 | 0.600 |
Why?
|
| Transportation | 1 | 2020 | 217 | 0.600 |
Why?
|
| Subacute Care | 1 | 2020 | 184 | 0.550 |
Why?
|
| Reimbursement, Incentive | 1 | 2021 | 541 | 0.530 |
Why?
|
| Stroke | 7 | 2023 | 9747 | 0.530 |
Why?
|
| Arthroplasty, Replacement | 1 | 2020 | 314 | 0.520 |
Why?
|
| Palliative Care | 8 | 2020 | 3645 | 0.500 |
Why?
|
| Marketing of Health Services | 1 | 2016 | 151 | 0.480 |
Why?
|
| Exercise Therapy | 2 | 2013 | 937 | 0.430 |
Why?
|
| Arthroplasty, Replacement, Knee | 2 | 2021 | 1379 | 0.430 |
Why?
|
| Hospitalization | 4 | 2024 | 10808 | 0.410 |
Why?
|
| Rural Population | 2 | 2020 | 2317 | 0.400 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 721 | 0.370 |
Why?
|
| United States | 26 | 2024 | 72903 | 0.360 |
Why?
|
| Patient Readmission | 2 | 2021 | 3286 | 0.340 |
Why?
|
| Antipsychotic Agents | 1 | 2023 | 3076 | 0.340 |
Why?
|
| Drug-Eluting Stents | 1 | 2016 | 683 | 0.340 |
Why?
|
| Thoracic Neoplasms | 1 | 2012 | 267 | 0.330 |
Why?
|
| Aged | 27 | 2024 | 171117 | 0.290 |
Why?
|
| Brain Ischemia | 1 | 2021 | 3000 | 0.290 |
Why?
|
| Electric Stimulation Therapy | 1 | 2013 | 635 | 0.290 |
Why?
|
| Quality of Health Care | 1 | 2021 | 4300 | 0.270 |
Why?
|
| Mental Disorders | 2 | 2023 | 6853 | 0.260 |
Why?
|
| Disease Management | 2 | 2020 | 2535 | 0.260 |
Why?
|
| Dyspnea | 3 | 2024 | 1352 | 0.250 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 1534 | 0.250 |
Why?
|
| Mass Media | 2 | 2018 | 301 | 0.230 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2013 | 1880 | 0.230 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 3413 | 0.230 |
Why?
|
| Emergency Medical Services | 1 | 2016 | 1938 | 0.230 |
Why?
|
| Patient Discharge | 3 | 2023 | 3461 | 0.230 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2006 | 639 | 0.220 |
Why?
|
| Myocardial Infarction | 1 | 2024 | 11499 | 0.220 |
Why?
|
| Neurology | 2 | 2022 | 785 | 0.210 |
Why?
|
| Insurance Claim Review | 2 | 2018 | 746 | 0.210 |
Why?
|
| Aged, 80 and over | 9 | 2024 | 59489 | 0.200 |
Why?
|
| Urban Population | 2 | 2020 | 2040 | 0.190 |
Why?
|
| Motor Activity | 1 | 2012 | 2704 | 0.190 |
Why?
|
| Patient-Centered Care | 3 | 2020 | 1458 | 0.190 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 13451 | 0.170 |
Why?
|
| Hospitals, Rural | 1 | 2022 | 175 | 0.170 |
Why?
|
| Humans | 40 | 2024 | 765968 | 0.160 |
Why?
|
| Rehabilitation | 1 | 2020 | 125 | 0.160 |
Why?
|
| Muscle, Skeletal | 1 | 2013 | 4958 | 0.150 |
Why?
|
| Thrombolytic Therapy | 3 | 2023 | 2059 | 0.150 |
Why?
|
| Physicians | 1 | 2016 | 4588 | 0.150 |
Why?
|
| Coronavirus | 1 | 2020 | 155 | 0.140 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2018 | 1188 | 0.140 |
Why?
|
| Aftercare | 1 | 2023 | 911 | 0.140 |
Why?
|
| Pandemics | 5 | 2023 | 8703 | 0.140 |
Why?
|
| Neoplasms | 4 | 2020 | 22340 | 0.140 |
Why?
|
| Treatment Outcome | 4 | 2024 | 65188 | 0.140 |
Why?
|
| Exercise | 1 | 2013 | 5937 | 0.140 |
Why?
|
| Female | 21 | 2024 | 396112 | 0.130 |
Why?
|
| Health Care Sector | 1 | 2018 | 196 | 0.130 |
Why?
|
| Quality of Life | 5 | 2020 | 13462 | 0.130 |
Why?
|
| Insurance Coverage | 2 | 2018 | 1944 | 0.130 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 26318 | 0.130 |
Why?
|
| Karnofsky Performance Status | 1 | 2016 | 163 | 0.130 |
Why?
|
| Advance Care Planning | 2 | 2020 | 702 | 0.130 |
Why?
|
| Outpatients | 1 | 2024 | 1595 | 0.130 |
Why?
|
| Nursing Homes | 1 | 2023 | 1084 | 0.120 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2024 | 939 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 5389 | 0.120 |
Why?
|
| Male | 19 | 2024 | 363698 | 0.120 |
Why?
|
| Medicine | 1 | 2023 | 942 | 0.120 |
Why?
|
| Fibrinolytic Agents | 2 | 2022 | 2080 | 0.120 |
Why?
|
| Patient Transfer | 1 | 2021 | 790 | 0.110 |
Why?
|
| Multiple Sclerosis | 2 | 2020 | 3213 | 0.110 |
Why?
|
| Middle Aged | 15 | 2024 | 223009 | 0.100 |
Why?
|
| Health Status Indicators | 1 | 2018 | 966 | 0.100 |
Why?
|
| Hospital Administration | 1 | 2016 | 352 | 0.100 |
Why?
|
| Psychiatry | 2 | 2021 | 1714 | 0.100 |
Why?
|
| Patient Participation | 1 | 2020 | 1455 | 0.090 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2024 | 3247 | 0.090 |
Why?
|
| Neurodegenerative Diseases | 1 | 2020 | 1087 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2023 | 41649 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2023 | 3050 | 0.090 |
Why?
|
| Australia | 3 | 2024 | 1258 | 0.080 |
Why?
|
| Air | 1 | 2010 | 181 | 0.080 |
Why?
|
| Hormones | 1 | 2013 | 863 | 0.080 |
Why?
|
| Immune System | 1 | 2013 | 799 | 0.070 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2019 | 1416 | 0.070 |
Why?
|
| Caregivers | 2 | 2020 | 2307 | 0.070 |
Why?
|
| Time Factors | 3 | 2021 | 40065 | 0.070 |
Why?
|
| Mass Screening | 1 | 2023 | 5446 | 0.070 |
Why?
|
| Psychometrics | 1 | 2016 | 3062 | 0.070 |
Why?
|
| Emergency Service, Hospital | 2 | 2023 | 7875 | 0.070 |
Why?
|
| Emotions | 1 | 2018 | 2763 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 9249 | 0.070 |
Why?
|
| Health Expenditures | 1 | 2019 | 2387 | 0.060 |
Why?
|
| Incidence | 1 | 2024 | 21480 | 0.060 |
Why?
|
| Mental Health | 1 | 2018 | 3278 | 0.060 |
Why?
|
| Health Services Accessibility | 2 | 2018 | 5508 | 0.060 |
Why?
|
| New Zealand | 1 | 2024 | 359 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2016 | 10070 | 0.050 |
Why?
|
| Disease Progression | 2 | 2020 | 13632 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 7425 | 0.050 |
Why?
|
| Adult | 9 | 2021 | 223044 | 0.050 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2024 | 426 | 0.050 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 3835 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3100 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3223 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 5370 | 0.050 |
Why?
|
| Substance-Related Disorders | 1 | 2018 | 4416 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2023 | 212 | 0.050 |
Why?
|
| Slovenia | 1 | 2020 | 22 | 0.050 |
Why?
|
| Belgium | 1 | 2020 | 119 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 15880 | 0.040 |
Why?
|
| Referral and Consultation | 2 | 2023 | 3615 | 0.040 |
Why?
|
| Double-Blind Method | 3 | 2024 | 12437 | 0.040 |
Why?
|
| Skilled Nursing Facilities | 1 | 2023 | 410 | 0.040 |
Why?
|
| Advance Directives | 1 | 2020 | 251 | 0.040 |
Why?
|
| Oxygen | 1 | 2010 | 4241 | 0.040 |
Why?
|
| Adaptation, Psychological | 2 | 2020 | 2660 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2023 | 796 | 0.040 |
Why?
|
| Italy | 1 | 2020 | 854 | 0.040 |
Why?
|
| Organizational Innovation | 1 | 2021 | 541 | 0.040 |
Why?
|
| Denmark | 1 | 2020 | 774 | 0.040 |
Why?
|
| Episode of Care | 1 | 2019 | 128 | 0.040 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 2016 | 82 | 0.030 |
Why?
|
| Censuses | 1 | 2017 | 197 | 0.030 |
Why?
|
| Netherlands | 1 | 2020 | 2277 | 0.030 |
Why?
|
| Private Sector | 1 | 2018 | 396 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2023 | 21056 | 0.030 |
Why?
|
| Sample Size | 1 | 2018 | 845 | 0.030 |
Why?
|
| Multiple System Atrophy | 1 | 2016 | 132 | 0.030 |
Why?
|
| Heart Failure | 1 | 2018 | 11840 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2018 | 642 | 0.030 |
Why?
|
| Inflammation | 1 | 2013 | 10850 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2006 | 8733 | 0.030 |
Why?
|
| Health Services Research | 1 | 2020 | 1808 | 0.030 |
Why?
|
| Young Adult | 4 | 2020 | 59889 | 0.020 |
Why?
|
| Mammography | 1 | 2023 | 2423 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 15398 | 0.020 |
Why?
|
| Europe | 1 | 2018 | 3423 | 0.020 |
Why?
|
| Medically Uninsured | 1 | 2017 | 838 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2016 | 54802 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2018 | 81514 | 0.020 |
Why?
|
| Epistaxis | 1 | 2010 | 119 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 14751 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2018 | 1950 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2023 | 3236 | 0.020 |
Why?
|
| Length of Stay | 1 | 2021 | 6485 | 0.020 |
Why?
|
| Mortality | 1 | 2018 | 2904 | 0.020 |
Why?
|
| Decision Making | 1 | 2020 | 3965 | 0.020 |
Why?
|
| Adolescent | 3 | 2020 | 88835 | 0.020 |
Why?
|
| Sleep Stages | 1 | 2010 | 698 | 0.020 |
Why?
|
| Communication | 1 | 2020 | 3916 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2020 | 9347 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2017 | 2521 | 0.010 |
Why?
|
| Medicaid | 1 | 2017 | 2833 | 0.010 |
Why?
|
| Logistic Models | 1 | 2018 | 13266 | 0.010 |
Why?
|
| Parkinson Disease | 1 | 2016 | 2895 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 20124 | 0.010 |
Why?
|
| Anxiety | 1 | 2010 | 4671 | 0.010 |
Why?
|
| Sleep | 1 | 2010 | 4813 | 0.010 |
Why?
|
| Child | 1 | 2018 | 80564 | 0.010 |
Why?
|